Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2024-06-26

Clinical Trial Update: A Study to Test How Kidney Problems Influence the Blood Concentrations of Efgartigimod [Phase 1]

View source ↗

Summary

Completed Phase 1 pharmacokinetic study evaluating how renal impairment influences blood concentrations of efgartigimod.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • VYVGART (EFGARTIGIMOD ALFA)

Snippet

Sponsor: argenx | Conditions: Renal Impairment | Phase 1 | Status: COMPLETED